Difference between revisions of "Alisertib (MLN-8237)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://ascopubs.org" to "https://ascopubs.org") |
Warner-admin (talk | contribs) m (Warner-admin moved page Alisertib (MLN8237) to Alisertib (MLN-8237) without leaving a redirect) |
||
| (16 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=561286 NCI Drug Dictionary]: A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=561286 NCI Drug Dictionary]: A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. | ||
| − | =Preliminary data= | + | ==Preliminary data== |
| − | ==[[Mantle cell lymphoma]]== | + | ===[[Mantle cell lymphoma]]=== |
| − | # Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. | + | # '''C14004:''' Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. [https://doi.org/10.1200/jco.2012.46.8793 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3867644/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24043741/ PubMed] [https://clinicaltrials.gov/study/NCT00807495 NCT00807495] |
| − | ==[[Peripheral T-cell lymphoma]]== | + | ===[[Peripheral T-cell lymphoma]]=== |
| − | # '''SWOG S1108:''' Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol. 2015 Jul 20;33(21):2399-404. Epub 2015 Jun 15. [ | + | # '''SWOG S1108:''' Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol. 2015 Jul 20;33(21):2399-404. Epub 2015 Jun 15. [https://doi.org/10.1200/jco.2014.60.6327 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4500834/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26077240/ PubMed] [https://clinicaltrials.gov/study/NCT01466881 NCT01466881] |
| − | # '''LUMIERE:''' | + | # '''LUMIERE:''' Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019 Mar 10;37(8):613-623. Epub 2019 Feb 1. [https://doi.org/10.1200/JCO.18.00899 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30707661/ PubMed] [https://clinicaltrials.gov/study/NCT01482962 NCT01482962] |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' MLN-8237 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:Aurora kinase inhibitors]] | [[Category:Aurora kinase inhibitors]] | ||
| − | [[Category:Mantle cell lymphoma medications]] | + | [[Category:Mantle cell lymphoma medications (investigational)]] |
| − | [[Category:Peripheral T-cell lymphoma medications]] | + | [[Category:Peripheral T-cell lymphoma medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Latest revision as of 22:04, 25 July 2023
Mechanism of action
From the NCI Drug Dictionary: A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation.
Preliminary data
Mantle cell lymphoma
- C14004: Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. link to original article link to PMC article PubMed NCT00807495
Peripheral T-cell lymphoma
- SWOG S1108: Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol. 2015 Jul 20;33(21):2399-404. Epub 2015 Jun 15. link to original article link to PMC article PubMed NCT01466881
- LUMIERE: Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019 Mar 10;37(8):613-623. Epub 2019 Feb 1. link to original article PubMed NCT01482962
Also known as
- Code name: MLN-8237